Response Genetics (RGDX) 0.0250 $RGDX
Cancer Genetics Announces Strong Second Quarter 2015 Results
M2 - Thu Sep 17, 4:27AM CDT
* Second Quarter Revenues up 177 Percent Year-over-Year; Six-Months Ended June 30, 2015 Revenues up 191 Percent Year-over-Year
ICLR: 67.54 (-1.22), CGIX: 2.05 (-0.08)
Cancer Genetics Announces Agreement in Principle to Acquire the Assets of Response Genetics, Inc. and Its Strong Franchise in Solid Tumor Molecular and Genomic Testing
GlobeNewswire - Mon Aug 10, 8:51AM CDT
-- Response Genetics' Los Angeles clinical lab and facility will allow Cancer Genetics to expand its national sales and service footprint and serve a broader customer base while adding immediate revenue from both clinical and biopharma customers
CGIX: 2.05 (-0.08)
Response Genetics Inc. Enters Into Asset Purchase Agreement With Cancer Genetics Inc.; Proposed Transaction to be Effectuated Through Voluntary Chapter 11; Business Uninterrupted
GlobeNewswire - Mon Aug 10, 7:50AM CDT
Response Genetics, Inc. (OTCQB:RGDX) (the "Company"
, a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, announced today that it has executed an asset purchase agreement (the "Purchase Agreement" with Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics, as a "stalking horse" bidder to acquire substantially all of the Company's assets. To facilitate the sale, the Company filed a voluntary petition under chapter 11 of the Bankruptcy Code in the Delaware Bankruptcy Court ("Court" to, among other things, seek approval to implement sale and bidding procedures.
CGIX: 2.05 (-0.08)
Great Basin Welcomes Kirk Calhoun to Board of Directors
PR Newswire - Tue Jun 02, 7:00AM CDT
Great Basin Scientific, Inc. (NASDAQ: GBSN, GBSNU), a molecular diagnostics company, today announced the election of Kirk Calhoun to its Board of Directors, effective May 27, 2015. Mr. Calhoun was elected to the board as an independent director during the Company's Annual Stockholder Meeting on May 27 in Salt Lake City. He will serve as the chair of the Company's Audit Committee. Mr. Calhoun joins Ryan Ashton, David Spafford, Ronald K. Labrum and Sam Chawla on the board, and replaces Steven Aldous, who is retiring from his director position.
GBSN: 1.74 (-0.09), RYI: 15.00 (-0.55), GBSNU: 16.22 (-0.28)
BUYINS.NET: CMG, SORL, HALO, HF, RGDX, MDAS Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Thu May 07, 6:41AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Computer Modelling Group Ltd (NYSE:CMG), Sorl Auto Parts Inc (NASDAQ:SORL), Halozyme Therapeutics Inc (NASDAQ:HALO), Hanfeng Evergreen Inc (NYSE:HF), Response Genetics Inc (NASDAQ:RGDX), MedAssets Inc (NASDAQ:MDAS) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
HF: 31.90 (-0.69), HALO: 8.75 (-0.22), CMG: 405.26 (-10.53), SORL: 1.85 (+0.07), MDAS: 31.35 (+0.01)
Response Genetics, Inc. to Release First Quarter 2015 Financial Results and Host Conference Call on May 14, 2015
GlobeNewswire - Thu May 07, 6:01AM CDT
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, will announce its first quarter financial results for 2015 and give an operational update in a press release to be issued before the market opens on Thursday, May 14, 2015. The company will host a conference call that same day at 10:00 a.m. Eastern time to discuss its financial results.
Response Genetics, Inc. Announces Fourth Quarter and Year-End 2014 Financial Results
GlobeNewswire - Tue Mar 31, 3:05PM CDT
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced its consolidated financial results and business progress for the fourth quarter and full year ended December 31, 2014.
Response Genetics, Inc. to Release Fourth Quarter and Year-End 2014 Financial Results and Host Conference Call on March 31, 2015
GlobeNewswire - Thu Mar 19, 1:07PM CDT
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, will announce its fourth quarter and year-end financial results for 2014 and give an operational update in a press release to be issued after the market closes on Tuesday, March 31, 2015. The company will host a conference call that same day at 4:30 p.m. Eastern time to discuss its financial results.
Latest Updates in Healthcare Sector: Special Research on OncoGenex, Oxford Immunotec, Quidel, Response Genetics, and Trinity Biotech
PR Newswire - Tue Mar 10, 7:10AM CDT
Editor Note: For more information about this release, please scroll to bottom.
OGXI: 1.08 (+0.07), QDEL: 16.89 (-0.54), TRIB: 10.93 (-0.27), OXFD: 8.91 (-0.06)
Response Genetics, Inc. Announces Presentations at the American Society of Clinical Oncology's Gastrointestinal Cancers Symposium 2015
GlobeNewswire - Thu Jan 15, 1:10PM CST
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced that the company will present two abstracts at the upcoming American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancers Symposium in San Francisco, CA, January 15 to 17, 2015. One presentation, entitled "Expanded KRAS and NRAS assays increase detection of mutations that predict for resistance to therapy in colorectal cancer patients" demonstrates the clinical utility of Response Genetics' proprietary ResponseDX KRAS and NRAS mutation detection tests in colorectal cancer. The other presentation, entitled "EGFR ligands and ERCC1 mRNA expression to predict clinical outcome in Japanese patients with metastatic colorectal cancer harboring overexpressed EGFR and KRAS exon 2 wild-type treated with cetuximab plus oxaliplatin-based chemotherapy (JACCRO CC-05/06 AR)" provides further clinical evidence for the company's patented ERCC1 mRNA expression technology in predicting response to chemotherapy.
Vermillion Strengthens Board of Directors with Appointments of Veronica Jordan, Ph.D., and David Schreiber
PR Newswire - Fri Dec 12, 8:00AM CST
Vermillion, Inc. (NasdaqCM: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today the appointments of Veronica G. H. Jordan, Ph.D., and David R. Schreiber to the Company's Board of Directors, bringing the total number of directors to eight, seven of whom are independent.
AMRI: 14.59 (-0.28), VRML: 1.27 (-0.02)
Cancer Genetics Announces Strong Second Quarter 2015 Results
M2 - Thu Sep 17, 4:27AM CDT
* Second Quarter Revenues up 177 Percent Year-over-Year; Six-Months Ended June 30, 2015 Revenues up 191 Percent Year-over-Year
ICLR: 67.54 (-1.22), CGIX: 2.05 (-0.08)
Cancer Genetics Announces Agreement in Principle to Acquire the Assets of Response Genetics, Inc. and Its Strong Franchise in Solid Tumor Molecular and Genomic Testing
GlobeNewswire - Mon Aug 10, 8:51AM CDT
-- Response Genetics' Los Angeles clinical lab and facility will allow Cancer Genetics to expand its national sales and service footprint and serve a broader customer base while adding immediate revenue from both clinical and biopharma customers
CGIX: 2.05 (-0.08)
Response Genetics Inc. Enters Into Asset Purchase Agreement With Cancer Genetics Inc.; Proposed Transaction to be Effectuated Through Voluntary Chapter 11; Business Uninterrupted
GlobeNewswire - Mon Aug 10, 7:50AM CDT
Response Genetics, Inc. (OTCQB:RGDX) (the "Company"
, a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, announced today that it has executed an asset purchase agreement (the "Purchase Agreement" with Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics, as a "stalking horse" bidder to acquire substantially all of the Company's assets. To facilitate the sale, the Company filed a voluntary petition under chapter 11 of the Bankruptcy Code in the Delaware Bankruptcy Court ("Court" to, among other things, seek approval to implement sale and bidding procedures. CGIX: 2.05 (-0.08)
Great Basin Welcomes Kirk Calhoun to Board of Directors
PR Newswire - Tue Jun 02, 7:00AM CDT
Great Basin Scientific, Inc. (NASDAQ: GBSN, GBSNU), a molecular diagnostics company, today announced the election of Kirk Calhoun to its Board of Directors, effective May 27, 2015. Mr. Calhoun was elected to the board as an independent director during the Company's Annual Stockholder Meeting on May 27 in Salt Lake City. He will serve as the chair of the Company's Audit Committee. Mr. Calhoun joins Ryan Ashton, David Spafford, Ronald K. Labrum and Sam Chawla on the board, and replaces Steven Aldous, who is retiring from his director position.
GBSN: 1.74 (-0.09), RYI: 15.00 (-0.55), GBSNU: 16.22 (-0.28)
BUYINS.NET: CMG, SORL, HALO, HF, RGDX, MDAS Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Thu May 07, 6:41AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Computer Modelling Group Ltd (NYSE:CMG), Sorl Auto Parts Inc (NASDAQ:SORL), Halozyme Therapeutics Inc (NASDAQ:HALO), Hanfeng Evergreen Inc (NYSE:HF), Response Genetics Inc (NASDAQ:RGDX), MedAssets Inc (NASDAQ:MDAS) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
HF: 31.90 (-0.69), HALO: 8.75 (-0.22), CMG: 405.26 (-10.53), SORL: 1.85 (+0.07), MDAS: 31.35 (+0.01)
Response Genetics, Inc. to Release First Quarter 2015 Financial Results and Host Conference Call on May 14, 2015
GlobeNewswire - Thu May 07, 6:01AM CDT
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, will announce its first quarter financial results for 2015 and give an operational update in a press release to be issued before the market opens on Thursday, May 14, 2015. The company will host a conference call that same day at 10:00 a.m. Eastern time to discuss its financial results.
Response Genetics, Inc. Announces Fourth Quarter and Year-End 2014 Financial Results
GlobeNewswire - Tue Mar 31, 3:05PM CDT
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced its consolidated financial results and business progress for the fourth quarter and full year ended December 31, 2014.
Response Genetics, Inc. to Release Fourth Quarter and Year-End 2014 Financial Results and Host Conference Call on March 31, 2015
GlobeNewswire - Thu Mar 19, 1:07PM CDT
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, will announce its fourth quarter and year-end financial results for 2014 and give an operational update in a press release to be issued after the market closes on Tuesday, March 31, 2015. The company will host a conference call that same day at 4:30 p.m. Eastern time to discuss its financial results.
Latest Updates in Healthcare Sector: Special Research on OncoGenex, Oxford Immunotec, Quidel, Response Genetics, and Trinity Biotech
PR Newswire - Tue Mar 10, 7:10AM CDT
Editor Note: For more information about this release, please scroll to bottom.
OGXI: 1.08 (+0.07), QDEL: 16.89 (-0.54), TRIB: 10.93 (-0.27), OXFD: 8.91 (-0.06)
Response Genetics, Inc. Announces Presentations at the American Society of Clinical Oncology's Gastrointestinal Cancers Symposium 2015
GlobeNewswire - Thu Jan 15, 1:10PM CST
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced that the company will present two abstracts at the upcoming American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancers Symposium in San Francisco, CA, January 15 to 17, 2015. One presentation, entitled "Expanded KRAS and NRAS assays increase detection of mutations that predict for resistance to therapy in colorectal cancer patients" demonstrates the clinical utility of Response Genetics' proprietary ResponseDX KRAS and NRAS mutation detection tests in colorectal cancer. The other presentation, entitled "EGFR ligands and ERCC1 mRNA expression to predict clinical outcome in Japanese patients with metastatic colorectal cancer harboring overexpressed EGFR and KRAS exon 2 wild-type treated with cetuximab plus oxaliplatin-based chemotherapy (JACCRO CC-05/06 AR)" provides further clinical evidence for the company's patented ERCC1 mRNA expression technology in predicting response to chemotherapy.
Vermillion Strengthens Board of Directors with Appointments of Veronica Jordan, Ph.D., and David Schreiber
PR Newswire - Fri Dec 12, 8:00AM CST
Vermillion, Inc. (NasdaqCM: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today the appointments of Veronica G. H. Jordan, Ph.D., and David R. Schreiber to the Company's Board of Directors, bringing the total number of directors to eight, seven of whom are independent.
AMRI: 14.59 (-0.28), VRML: 1.27 (-0.02)
